Company Announcements
Date
Title
29 March
First patient treated in QBiotics’ Phase II Clinical Trial treating head and neck cancer with tigilanol tiglate
7 March
31 December 2022 Interim Financial Report
14 February
QBiotics announces amended human clinical strategy for tigilanol tiglate and Non-executive Director resignation
22 December
Presentation of new pre-clinical data
11 December
Update of QBiotics Group human oncology clinical trials
8 December
QBiotics appoints new Chair and Deputy Chair
2 December
Resignation of non-executive chair
21 November
Annual General Meeting CEO Presentation 2022
13 September
30 June 2022 Annual Report
25 July
FDA approves IND to initiate soft tissue sarcoma (STS) trial
22 March
COVID-19 impact update
14 March
31 December 2021 Interim Financial Report
2 March
Phase I/II trial (QBC46-H03) completes recruitment
15 December
STELFONTA® launches in Australia
7 July
APVMA approves registration of STELFONTA
28 June
QBiotics concludes successful $85 million capital raise
3 June
First patient dosed in QBiotics and MSD clinical trial collaboration for unresectable melanoma
25 May
Prospectus – Offer opens and Application Forms now available
17 May
QBiotics lodges Prospectus in preparation for share offer to Existing Shareholders
20 April
QBiotics raises AU$22.55 million from existing Sophisticated Investors
9 April
Hamish Corlett joins the Board of QBiotics
1 April
QBiotics announces plan to increase capital raise to up to AU$85 million
16 March
Cornerstone Investor Joins QBiotics
16 March
QBiotics announces plan to raise up to AU$75 million
16 March
QBiotics welcomes TDM Growth Partners as cornerstone investor
24 February
QBiotics’ first USA shipment of STELFONTA®
1 February
Nicholas Moore joins the Board of QBiotics
17 November
FDA approves registration of STELFONTA®
21 September
STELFONTA® USA Marketing Authorisation Progress
13 August
QBiotics announces clinical collaboration with MSD targeting unresectable melanoma
22 July
QBiotics doses first Australian patient in Phase I/II clinical trial for head and neck cancer
17 June
Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA® (tigilanol tiglate) removes 75% of tumours
27 April
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
February
QBiotics raises AU$17.76 million from Sophisticated Investors
20 January
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA®
10 December
The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal
3 December
QBiotics announces first patient dosed in its Phase I/II clinical trial of tigilanol tiglate for head and neck cancer
November
STELFONTA Progress with European Medicines Authority
14 October
Dr Susan Foden joined the Board of QBiotics
October
Scientific Presentations: Veterinary Cancer Society, Houston, USA
September
Tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results presented at prestigious international congresses
April
International Publication - Tigilanol Tiglate Canine Dose Characterisation Study
December
QBiotics closes successful Share Offer
November
Positive results announced with first in-human study of tigilanol tiglate in solid tumours
November
Prospectus approved by ASIC and opening of QBiotics Group capital raise
October
QBiotics prepares for a new capital raise
October
Completion of QBiotics USA veterinary anti-cancer trial in USA treating dogs with Mast Cell Tumours
August
QBiotics signs supply, marketing and distribution agreement with Virbac for canine cancer treatment